1stOncology™: Cancer Intelligence Service – Page 13086 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Luminex Corporation First Quarter Earnings Release Scheduled for May 6, 2019

On April 18, 2019 Luminex Corporation (NASDAQ: LMNX) reported that it plans to report results for the first quarter ended March 31, 2019 on Monday, May 6, 2019 (Press release, Luminex, APR 18, 2019, View Source [SID1234535214]). A press release announcing the results is scheduled for release after the close of trading on that date.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Management will hold a conference call to discuss the operating highlights and financial results for the first quarter ended March 31, 2019 on May 6, 2019, at 4:30 p.m. Eastern time.

The conference call will be webcast live and may be accessed at Luminex Corporation’s website at View Source Simply log on to the website, go to the About Luminex section and access the Investor Relations link. If you are unable to participate during the live webcast, the call will be archived for six months on the website using the ‘replay’ link.

Vanda Pharmaceuticals to Announce First Quarter 2019 Financial Results on May 1, 2019

On April 18, 2019 Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) reported it will release results for the first quarter 2019 on Wednesday, May 1, 2019, after the market closes (Press release, Vanda Pharmaceuticals, APR 18, 2019, View Source [SID1234535212]).

Vanda will host a conference call at 4:30 PM ET on Wednesday, May 1, 2019, during which management will discuss the first quarter 2019 financial results and other corporate activities. To participate in the conference call, please dial 1-866-688-9426 (domestic) or 1-409-216-0816 (international) and use passcode 6195579.

The conference call will be broadcast simultaneously and archived on Vanda’s website, www.vandapharma.com. Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Wednesday, May 1, 2019, beginning at 7:30 PM ET and will be accessible until Wednesday, May 8, 2019, at 11:59 PM ET. The replay call-in number is 1-855-859-2056 for domestic callers and 1-404-537-3406 for international callers. The passcode number is 6195579.

AqVida and Phyton Biotech Receive Approval from European Directorate of Quality Medicines for AqVida’s Cancer-fighting Paclitaxel Injectable Finished Dosage Formulation

On April 18, 2019 Phyton Biotech, a German/North American Plant Cell Fermentation (PCF) technology company, and AqVida, a German oncology Finished Dosage Formulation (FDF) manufacturer, reported that they have received European approval from the EDQM (European Directorate of Quality Medicines) for AqVida’s paclitaxel injectable FDF (Press release, Phyton Biotech, APR 18, 2019, View Source [SID1234535211]).

Phyton Biotech is the world’s leading manufacturer of paclitaxel active pharmaceutical ingredient (API), utilizing its prorprietary PCF technology process. Under the strategic partnership with AqVida, Phyton Biotech will be the exclusive supplier of paclitaxel API for AqVida’s Taxol generic formulation, which is produced in AqVida’s new state-of-the-art injectable manufacturing facility located in Dassow, Germany. AqVida’s ultramodern robotic manufacturing line, designed for filling cytotoxic injectables, will be utilized to produce AqVida’s generic oncology medicines to treat common types of cancer.

"We chose to work with Phyton because of the company’s superior quality fermentation-produced API, in comparison to naturally extracted or semi-synthetically produced alternatives," says Wolfgang Heinze, who is the Chief Executive Officer (CEO) of AqVida. "Approval of ourpaclitaxel injectable FDF by the European Directorate of Quality Medicines is a major milestone for our company."

Recognized for its innovative and broad portfolio of generic oncology medicines, AqVida is a leading German oncology medication supplier that distributes its products globally.

"We are proud to partner with AqVida and assist with the expansion of its oncology product line," says Colin Marr, president of Phyton Biotech. "Phyton is committed to working with trusted pharmaceutical partners who seek to improve the quality of oncology medicines."

ImmunoGen Announces Conference Call to Discuss Its First Quarter 2019 Operating Results

On April 18, 2019 ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, reported that the Company will host a conference call at 8:00 a.m. ET on Friday, May 3, 2019 to discuss its first quarter operating results (Press release, ImmunoGen, APR 18, 2019, View Source [SID1234535210]). Management will also provide a brief update on the business.

Conference Call Information
To access the live call by phone, dial 323-994-2093; the conference ID is 8980567. The call may also be accessed through the Investors and Media section of the Company’s website, www.immunogen.com. Following the webcast, a replay of the call will be available at the same location through May 17, 2019.

Vaxiion Therapeutics Initiates Phase 1 Clinical Trial of VAX014 for the Treatment of Non-Muscle Invasive Bladder Cancer in the United States

On April 18, 2019 Vaxiion Therapeutics, the industry leader in bacterial minicell-based targeted therapeutics, reported that the U.S. Food and Drug Administration (FDA) has concluded its 30-day review of the Investigational New Drug application (IND) for VAX014, and the company will now initiate a Phase 1 clinical trial for the treatment of non-muscle invasive bladder cancer (NMIBC) (Press release, Vaxiion Therapeutics, APR 18, 2019, View Source [SID1234535209]). VAX014 is a first-in-class recombinant bacterial minicell-based oncolytic immunotherapy that is engineered to selectively target a pair of NMIBC-associated cell-surface integrin heterodimers.

The study is a multi-center open label dose escalation with dose expansion Phase 1 trial evaluating the safety, tolerability, and initial anti-tumor activity in patients with NMIBC.

"Advancing our first product candidate into clinical trials is a major milestone, signifying Vaxiion’s transition to a clinical stage company," said Vaxiion President, Matthew Giacalone. "We are now one step closer to achieving our ultimate goal of filling the unmet needs existing in the gaps of the current non-muscle invasive bladder cancer treatment algorithm."

In preclinical models of NMIBC and other cancer types, VAX014 has repeatedly demonstrated durable anti-tumor immunotherapeutic activity resulting in complete tumor regressions and the development of long-term anti-tumor immunologic memory. In nonclinical safety studies, VAX014 was well tolerated following repeat dose administration in the clinically relevant dose range.

This first-in-human Phase 1 study will consist of two segments: a dose escalation segment and a dose expansion segment. Additional information about the trial can be found at View Source

VAX014 is the first clinical product candidate generated from Vaxiion’s proprietary recombinant bacterial-minicell delivery platform.